Durable efficacy of risankizumab through week 148 in patients with moderate-to-severe Crohn’s Disease: a post hoc analysis of part 2 of the SEQUENCE study
Zeitschrift für Gastroenterologie · 01.08.2026 · 64 (08) · e316-e317
DOI: 10.1055/s-0046-1826516 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.08.2026. Verfasst von R Atreya und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Atreya, R., Lindsay, J. O., Ferrante, M., Siegmund, B., Cao, Q., Haaren, S. V., Crowley, J., Anschutz, T., Garrison, A., Huang, X., & Dubinsky, M. (2026). Durable efficacy of risankizumab through week 148 in patients with moderate-to-severe Crohn’s Disease: a post hoc analysis of part 2 of the SEQUENCE study. Zeitschrift für Gastroenterologie, 64(08), e316-e317. https://doi.org/10.1055/s-0046-1826516
Vancouver
Atreya R, Lindsay JO, Ferrante M, Siegmund B, Cao Q, Haaren SV, et al. Durable efficacy of risankizumab through week 148 in patients with moderate-to-severe Crohn’s Disease: a post hoc analysis of part 2 of the SEQUENCE study. Zeitschrift für Gastroenterologie. 2026;64(08):e316-e317. doi:10.1055/s-0046-1826516
BibTeX
@article{Atreya2026,
author = {Atreya, R and Lindsay, J O and Ferrante, M and Siegmund, B and Cao, Q and Haaren, S van and Crowley, J and Anschutz, T and Garrison, A and Huang, X and Dubinsky, M},
title = {Durable efficacy of risankizumab through week 148 in patients with moderate-to-severe Crohn’s Disease: a post hoc analysis of part 2 of the SEQUENCE study},
journal = {Zeitschrift für Gastroenterologie},
year = {2026},
volume = {64},
number = {08},
pages = {e316--e317},
doi = {10.1055/s-0046-1826516}
}
EUVIMED